11039

L-Arginine monohydrochloride

≥99.5% (AT), suitable for ligand binding assays, BioUltra

• Synonym(s): (S)-(+)-2-Amino-5-[(aminoiminomethyl)amino]pentanoic acid monohydrochloride, (S)-(+)-Arginine hydrochloride
• Empirical Formula (Hill Notation): C₆H₁₄N₄O₂ · HCl
• CAS Number: 1119-34-2
• Molecular Weight: 210.66
• Beilstein: 3631658
• EC Number: 214-275-1
• MDL number: MFCD00064550
• UNSPSC Code: 12352209
• PubChem Substance ID: 57646880
• NACRES: NA.26

Properties

• Product Name: L-Arginine monohydrochloride, BioUltra, ≥99.5% (AT)
• product line: BioUltra
• Quality Level: 200
• Assay: ≥99.5% (AT)
• form: powder or crystals
• optical activity: [α]20/D +22.0±0.5°, c = 5% in 5 M HCl
• technique(s): ligand binding assay: suitable
• impurities: insoluble matter, passes filter test; ≤0.3% foreign amino acids
• ign. residue: ≤0.05%
• loss: ≤0.05% loss on drying, 20 °C (HV)
• color: colorless or white
• pH: 5.5-7.0 (25 °C, 1 M in H₂O)
• mp: 220-230 °C
• solubility: H₂O: 1 M at 20 °C, clear, colorless
• density: 1.42 g/cm³ at 20 °C
• anion traces: sulfate (SO₄^2-): ≤50 mg/kg
• cation traces: Al: ≤5 mg/kg; As: ≤0.1 mg/kg; Ba: ≤5 mg/kg; Bi: ≤5 mg/kg; Ca: ≤10 mg/kg; Cd: ≤5 mg/kg; Co: ≤5 mg/kg; Cr: ≤5 mg/kg; Cu: ≤5 mg/kg; Fe: ≤5 mg/kg; K: ≤50 mg/kg; Li: ≤5 mg/kg; Mg: ≤5 mg/kg; Mn: ≤5 mg/kg; Mo: ≤5 mg/kg; Na: ≤50 mg/kg; Ni: ≤5 mg/kg; Pb: ≤5 mg/kg; Sr: ≤5 mg/kg; Zn: ≤5 mg/kg
• λ: 1 M in H₂O
• UV absorption: λ: 260 nm A_max: ≤0.2; λ: 280 nm A_max: ≤0.1
• SMILES string: Cl[H].N[C@@H](CCCNC(N)=N)C(O)=O
• InChI: 1S/C6H14N4O2.ClH/c7-4(5(11)12)2-1-3-10-6(8)9;/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);1H/t4-;/m0./s1
• InChI key: KWTQSFXGGICVPE-WCCKRBBISA-N

Description

Application

L-Arginine monohydrochloride has been used to study the reversal of the inhibitory effect of L-N^G0-nitroarginine on non-cholinergic relaxations. It has also been used as a dietary supplement to study its effect on endothelium-dependent vasodilation.

Biochem/physiol Actions

L-Arginine is considered as a semi essential amino acid. In most mammals including humans, L-Arginine synthesis occurs through intestinal-renal axis, from glutamine, glutamate and proline. Abnormal levels of L-Arginine is associated with the development of kidney and cardiovascular disease. L-arginine is found to decrease fat mass and visceral adiposity.

Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.

Safety Information

• Storage Class Code: 13 - Non Combustible Solids
• WGK: WGK 1
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves